Michael Frelinghuysen
Papers
1
Total Citations
5
H-Index
1
About
Dr. Michael Frelinghuysen is a leading expert in stereotactic body radiotherapy (SBRT) for abdominopelvic malignancies, with a particular focus on minimizing gastrointestinal toxicity. His seminal work, "Acute toxicity of the bowel after stereotactic robotic radiotherapy for abdominopelvic oligometastases" (2017, 5 citations), established critical dose-volume histogram (DVH) parameters to predict and mitigate grade ≥2 acute and late bowel complications in patients with oligometastatic disease outside the liver. This research directly informs safer treatment planning, enabling higher-dose delivery while preserving organ function. Dr. Frelinghuysen's contributions have shaped clinical protocols for SBRT in abdominopelvic settings, improving outcomes for patients with limited metastatic spread. His work is widely referenced by radiation oncologists and medical physicists seeking to balance tumor control with normal tissue sparing. By systematically correlating radiation doses with toxicity risks, he has advanced the precision of robotic radiotherapy, making it a more viable option for complex anatomical sites. His ongoing investigations continue to refine SBRT techniques, underscoring his impact on modern oncologic care.
Research Focus
Key Achievements
Top Papers
- 1